GlassScriptPhysician profile
Mark C Priola
NPI 1407161235
$2,824.00
in general payments reported to CMS, 2019-2025
30 companies · $796 in 2025
The $796 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $580 · 2022: $791 · 2023: $232 · 2024: $425 · 2025: $796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,453.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $671.79 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $296.68 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $251.49 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $204.43 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $163.42 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $159.04 | 2021-2025 | Mounjaro, Zepbound, Kisunla |
| Watermark Medical, INC. | $143.92 | 2021 | |
| Dexcom, INC. | $120.98 | 2021-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $106.18 | 2022-2025 | |
| Astellas Pharma US INC | $89.96 | 2022-2025 | Veozah |
| Abbott Laboratories | $76.74 | 2022-2024 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $69.97 | 2025 | Caplyta |
| Alnylam Pharmaceuticals INC. | $47.96 | 2021-2025 | Givlaari |
| Biohaven Pharmaceutical Holding Company LTD. | $45.83 | 2022 | |
| Amgen INC. | $43.20 | 2021-2025 | Repatha, Otezla |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $34.28 | 2021 | |
| Esperion Therapeutics, INC. | $34.14 | 2021 | |
| Novartis Pharmaceuticals Corporation | $33.22 | 2022 | |
| Mylan Specialty L.P. | $26.47 | 2024 | Yupelri |
| Jazz Pharmaceuticals INC. | $22.32 | 2022 | |
| Renalytix Ai, INC. | $22.30 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Medtronic, INC. | $21.35 | 2024 | Kyphon Express II Kyphopak Tray |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.28 | 2021 | |
| Xeris Pharmaceuticals, INC. | $19.65 | 2025 | Recorlev |
| Saluda Medical Americas, INC. | $19.09 | 2024 | Evoke |
| Janssen Pharmaceuticals, INC | $18.65 | 2022 | |
| Idorsia Pharmaceuticals US INC | $16.92 | 2022 | |
| Pfizer INC. | $14.84 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $14.41 | 2021 | |
| Currax Pharmaceuticals LLC | $13.49 | 2024 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Priola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.